GEMOX方案联合干扰素治疗晚期原发性肝癌32例的临床分析

Clinical Analysis of 32 Cases of Gem and L-OHP with Interferon Regimen for the Treatment of Patients with Advanced Primary Liver Cancer

目的:观察GEMOX方案联合干扰素治疗晚期原发性肝癌的近期疗效和不良反应。方法:32例晚期原发性肝癌均采用GEMOX方案联合干扰素进行化疗及生物治疗,吉西他滨1000 mg/m2,静脉滴注,第1,8天;奥沙利铂100 mg/m2,静脉滴注,第1,8天。21天为一个周期。干扰素600 MIU ih QOD,连用6周。结果:所有患者均完成>2个周期的GEMOX方案联合干扰素治疗,疾病控制率为65.63%,部分缓解率15.63%,疾病稳定率50%。主要不良反应是骨髓抑制和神经毒性,经治疗均恢复。结论:GEMOX方案联合干扰素治疗晚期原发性肝癌,近期疗效确切,毒副作用可耐受,远期疗效有待观察。

Objective： To evaluate the efficacy and adverse events of Gem＋L-OHP（Gemcitabine;Oxaliplatin） with interferon regimen on advanced primary liver cancer（PLC）.Methods： A total of 32 patients with advanced primary liver cancer accepted Gem＋L-OHP with interferon regimen for 2 cycles.Gem＋L-OHP with interferon regimen： Gemcitabine 1000mg/m2ivgtt d1,d8;L-OHP 100 mg/m2ivgtt d1,8.21d as a cycle.The efficancy and adverse events were evaluated.Results： Of the 32 patients,the disease control rate was 65.63%.The response rates of partial response（PR） and stable disease（SD） were15.63% and 50% respectively;The major adverse effects were bone marrow depression and neurotoxicity.Conclusion： Gem＋L-OHP with interferon is a safe and effective regimen for the patients with advanced primary liver cancer.